Barclays Maintains Underweight on Insulet, Lowers Price Target to $198

Benzinga Newsdesk www.benzinga.com Negative 94.1%

Neg 94.1% Neu 0% Pos 0%

Barclays analyst Matt Miksic maintains Insulet (NASDAQ:PODD) with a Underweight and lowers the price target from $286 to $198.